{
  "meta": {
    "title": "Nucleotides",
    "url": "https://brainandscalpel.vercel.app/nucleotides-897312fb.html",
    "scrapedAt": "2025-11-29T18:23:29.104Z"
  },
  "questions": [
    {
      "id": 9340,
      "choices": [
        {
          "id": 37327,
          "text": "<p><span style=\"font-size:12.0pt;\">Uracil</span></p>"
        },
        {
          "id": 37328,
          "text": "<p><span style=\"font-size:12.0pt;\">Thymine</span></p>"
        },
        {
          "id": 37329,
          "text": "<p><span style=\"font-size:12.0pt;\">Orotate</span></p>"
        },
        {
          "id": 37330,
          "text": "<p><span style=\"font-size:12.0pt;\">Aspartate</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 5-month-old baby has developmental delay, and the blood work shows megaloblastic anaemia, though B12 and folate are in the higher range. Urinalysis shows formation of a crystalline substance upon standing. Supplementation of the child’s diet with uridine reversed all the clinical symptoms. The crystalline substance is composed of which of the following?</span></p>",
      "unique_key": "Q5472910",
      "question_audio": null,
      "question_video": null,
      "map_id": 30372,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. C. Orotate</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The child is <strong>diagnosed</strong> to have <strong>hereditary orotic aciduria</strong>, which is due to a <strong>mutation in UMP synthase </strong>→ <strong>leads to orotic acid accumulation in the urine.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">On <strong>treatment</strong> with <strong>uridine</strong>, the <strong>block is bypassed</strong> and <strong>allows UTP, CTP </strong>and <strong>dTTP synthesis.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">Uridine treatment has the beneficial effect of blocking.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanaton:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A</strong>. <strong>Uracil</strong> - While uracil is a <strong>pyrimidine base</strong>, the clinical scenario specifically points to the <strong>accumulation of orotate</strong>, a precursor in the pyrimidine synthesis pathway, not uracil itself.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B</strong>. <strong>Thymine</strong> - Thymine is another <strong>pyrimidine base</strong> found in <strong>DNA,</strong> but the condition described does not lead to thymine accumulation.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D</strong>. <strong>Aspartate</strong> - Aspartate is an <strong>amino acid</strong> involved in <strong>various metabolic processes,</strong> including the urea cycle and nucleotide synthesis, but it is not the crystalline substance described in this case.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Hereditary orotic aciduria</strong>, a <strong>rare autosomal recessive disorder</strong>, characterized by a <strong>deficiency in the enzyme UMP synthase,</strong> crucial for the <strong>de novo synthesis </strong>of <strong>pyrimidine nucleotides</strong>. The deficiency leads to an accumulation of orotic acid, which is excreted in the urine and can crystallize.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Ref</u>: Vasudevan 9/e: p 587.</strong></span></p>",
      "correct_choice_id": 37329,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9323,
      "choices": [
        {
          "id": 37259,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspartate</span></span></span></p>"
        },
        {
          "id": 37260,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glutamine</span></span></span></p>"
        },
        {
          "id": 37261,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Glycine</span></span></span></p>"
        },
        {
          "id": 37262,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alanine</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During pyrimidine nucleotide synthesis, one of the amino acids donates a nitrogen atom to form the pyrimidine ring. Which amino acid contributes the nitrogen at the N1 position in this structure?</span></span></p>",
      "unique_key": "Q7933441",
      "question_audio": null,
      "question_video": null,
      "map_id": 30364,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A. Aspartate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Aspartate</strong> provides the <strong>nitrogen atom </strong>at the <strong>N1 position of the pyrimidine ring in the synthesis of pyrimidine nucleotides.</strong> This occurs in the <strong>reaction catalyzed</strong> by the <strong>enzyme aspartate transcarbamoylase,</strong> where <strong>aspartate</strong> and <strong>carbamoyl phosphate</strong> combine to <strong>form carbamoyl aspartate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/11/5_Io3StVi.jpg\" style=\"height:305px; width:500px\" /></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Glutamine: </strong>Glutamine <strong>donates nitrogen atoms </strong>during <strong>purine nucleotide synthesis</strong>, not for the N1 position of pyrimidines.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. <strong>Glycine: </strong>Glycine contributes to the <strong>purine nucleotide structure</strong>, not the pyrimidine.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> <strong>Alanine:</strong> Alanine does <strong>not contribute nitrogen atoms</strong> to the pyrimidine ring structure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CONTRIBUTORS OF PYRIMIDINE RING:&nbsp; </span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">N3 by Amide Nitrogen of Glutamine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">C2 by CO2</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">C4, C5, C6, N1 by Aspartate&nbsp;&nbsp; </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span style=\"font-size:12.0pt\">: Harper 30/e: p 347-348.</span></strong></span></span></p>",
      "correct_choice_id": 37259,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9327,
      "choices": [
        {
          "id": 37275,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lesch-Nyhan syndrome</span></span></span></p>"
        },
        {
          "id": 37276,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gout</span></span></span></p>"
        },
        {
          "id": 37277,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Xanthine oxidase hyperactivity</span></span></span></p>"
        },
        {
          "id": 37278,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carbamoyl phosphate synthetase deficiency</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An evaluating patients with potential metabolic disorders, identifying conditions that are less likely to present with hyperuricemia is crucial for differential diagnosis. Which of the following conditions would make the presence of hyperuricemia very unlikely in a patient?</span></span></p>",
      "unique_key": "Q6694400",
      "question_audio": null,
      "question_video": null,
      "map_id": 30365,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D. Carbamoyl phosphate synthetase deficiency</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbamoyl phosphate</strong> (CAP) <strong>synthase I </strong>is found in <strong>mitochondrial matrix </strong>and is the <strong>first step in urea synthesis</strong>, condensing <strong>CO2 </strong>and <strong>NH4+.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri,sans-serif; font-size:12pt\"><strong>Hyperammonemia</strong> occurs when <strong>CAP is deficient.</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>CAP synthase II </strong>forms <strong>CAP</strong> as the <strong>first step in pyrimidine synthesis</strong> and its <strong>complete deficiency</strong> would probably be a <strong>lethal mutation</strong> and when its <strong>activity is decreased,</strong> <strong>purine catabolism</strong> to <strong>uric acid is decreased,</strong> <strong>decreasing</strong> the <strong>possibility of hyperuricemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">. <strong>Lesch-Nyhan syndrome</strong>: This condition is characterized by a <strong>deficiency in the enzyme HPRT</strong> and is associated with <strong>hyperuricemia</strong> due to the <strong>accumulation of uric acid.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Gout</strong>: Gout is <strong>directly associated with hyperuricemia,</strong> as it is caused by the deposition of urate crystals in joints due to elevated levels of uric acid in the blood.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. <strong>Xanthine oxidase hyperactivity</strong>: <strong>Increased activity </strong>of <strong>xanthine oxidase</strong> would lead to <strong>increased conversion </strong>of <strong>hypoxanthine</strong> and <strong>xanthine to uric acid,</strong> potentially resulting in hyperuricemia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbamoyl phosphate synthetase</strong> (CPS) deficiency is a <strong>urea cycle disorder</strong> that results in an <strong>inability to convert ammonia</strong> into <strong>urea,</strong> leading to <strong>hyperammonemia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">: DM Vasudevan 9/e: p 272,511.</span></strong></span></span></p>",
      "correct_choice_id": 37278,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9329,
      "choices": [
        {
          "id": 37283,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Aspartate transcarbamoylase</span></span></span></p>"
        },
        {
          "id": 37284,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypoxanthine-guanine phosphoribosyl transferase (HGPRT)</span></span></span></p>"
        },
        {
          "id": 37285,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Thymidylate synthase</span></span></span></p>"
        },
        {
          "id": 37286,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ribose-phosphate pyrophosphokinase</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is the rate-controlling step of pyrimidine synthesis which exhibits allosteric inhibition by cytidine triphosphate (CTP)?</span></span></span></p>",
      "unique_key": "Q3745668",
      "question_audio": null,
      "question_video": null,
      "map_id": 30366,
      "difficulty_level": "difficult",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A. Aspartate transcarbamoylase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It <strong>catalyses </strong>the <strong>first reaction of pyrimidine biosynthesis. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This <strong>enzyme is inhibited </strong>by <strong>CTP and activated by ATP. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Both <strong>ATP</strong> and <strong>CTP bind</strong> at a <strong>different site</strong> from <strong>either substrate. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Aspartate transcarbamoylase </strong>consists of <strong>multiple catalytic</strong> and <strong>regulatory subunits. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Each <strong>regulatory subunit</strong> contains at <strong>least two CTP binding sites</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. <strong>Hypoxanthine-guanine phosphoribosyl transferase </strong>(HGPRT): The <strong>free purines </strong>are <strong>salvaged by two different enzymes</strong>; adenine phosphoribosyl transferase (APRTase) and hypoxanthine guanine phosphoribosyl transferase (HGPRTase).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. <strong>Thymidylate synthase:</strong> The <strong>methyl group</strong> is <strong>donated by N5,N10-methylene</strong>- THFA. The thymine nucleotide is formed by thymidylate synthase by methylation of dUMP and fluorouracil will inhibit the enzyme, thereby reducing the conversion of dUMP to dTMP.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D</span></strong><span style=\"font-size:12.0pt\">. <strong>Ribose-phosphate pyrophosphokinase</strong>: In <strong>purine biosynthesis</strong>, <strong>Ribose-5-phosphate</strong> + <strong>ATP </strong>&rarr; <strong>ADP </strong>+ Phosphoribosyl pyrophosphate (PRPP), is the donor of ribose-5-phosphate for de novo synthesis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Aspartate transcarbamoylase</strong> (ATCase) is the <strong>rate-controlling enzyme</strong> of <strong>pyrimidine synthesis</strong> that is <strong>allosterically inhibited</strong> by <strong>cytidine triphosphate</strong> (CTP).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">: DM Vasudevan 9/e: p 586.</span></strong></span></span></p>",
      "correct_choice_id": 37283,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9331,
      "choices": [
        {
          "id": 37291,
          "text": "<p><span style=\"font-size:12.0pt;\">Addition of nucleotides to RNA during transcription of proviral cDNA</span></p>"
        },
        {
          "id": 37292,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of a phosphodiester bond during viral DNA synthesis</span></p>"
        },
        {
          "id": 37293,
          "text": "<p><span style=\"font-size:12.0pt;\">Formation of a peptide bond during translation of viral proteins</span></p>"
        },
        {
          "id": 37294,
          "text": "<p><span style=\"font-size:12.0pt;\">Hydrolysis of a phosphodiester bond during viral DNA synthesis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old woman, recently diagnosed as HIV-positive following exposure from her partner, begins treatment with dideoxycytidine, a nucleoside analog used in antiviral therapy. This medication exerts its effect by interfering with a specific step in the viral replication process. Which of the following best describes the action of dideoxycytidine in inhibiting HIV replication?</span></p>",
      "unique_key": "Q9056796",
      "question_audio": null,
      "question_video": null,
      "map_id": 30367,
      "difficulty_level": "difficult",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Formation of a phosphodiester bond during viral DNA synthesis.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Dideoxycytidine (ddC)</strong>, also known as <strong>zalcitabine</strong>, is a <strong>nucleoside analog reverse transcriptase inhibitor (NRTI)</strong>. It closely resembles cytidine but <strong>lacks a 3’-hydroxyl (-OH) group</strong> on its deoxyribose sugar.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">During <strong>reverse transcription</strong>, HIV reverse transcriptase incorporates ddC into the growing strand of viral DNA. However, the <strong>absence of the 3’-OH group</strong> means that <strong>no new phosphodiester bond can form</strong> with the next nucleotide. This causes <strong>chain termination</strong>, effectively halting DNA synthesis and preventing further viral replication.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\"><strong>Option A: Addition of nucleotides to RNA during transcription of proviral cDNA</strong> – Incorrect. ddC acts during reverse transcription (RNA → DNA), not during the transcription of DNA to RNA.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Option C: Formation of a peptide bond during translation of viral proteins</strong> – Incorrect. ddC doesn’t interfere with protein synthesis or translation.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Option D: Hydrolysis of a phosphodiester bond during viral DNA synthesis</strong> – Incorrect. ddC <strong>prevents</strong> bond formation; it doesn’t break existing bonds.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span><br><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Understand how <strong>NRTIs like dideoxycytidine</strong> act by causing <strong>premature chain termination</strong> during the reverse transcription step of the HIV life cycle. This directly disrupts viral DNA synthesis and is a key antiviral mechanism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Ref: Vasudevan 7/e: p706.</span></p>",
      "correct_choice_id": 37292,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9334,
      "choices": [
        {
          "id": 37303,
          "text": "<p><span style=\"font-size:12.0pt;\">True</span></p>"
        },
        {
          "id": 37304,
          "text": "<p><span style=\"font-size:12.0pt;\">False</span></p>"
        },
        {
          "id": 37305,
          "text": "<p><span style=\"font-size:12.0pt;\">Cannot say</span></p>"
        },
        {
          "id": 37306,
          "text": "<p><span style=\"font-size:12.0pt;\">None of the above</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent known for its action on nucleotide metabolism pathways. It specifically targets the synthesis of thymidylate (TMP) in pyrimidine biosynthesis, an essential process for DNA replication and cell division. Considering this mechanism, is the following statement accurate: \"5-Fluorouracil inhibits the synthesis of TMP in pyrimidine biosynthesis\"?</span></p>",
      "unique_key": "Q8069144",
      "question_audio": null,
      "question_video": null,
      "map_id": 30369,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans.</strong> <strong>A. True</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span><br><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>5-Fluorouracil (5-FU)</strong> is a <strong>pyrimidine analog</strong> that functions as an anticancer drug. It is <strong>converted intracellularly to 5-fluoro-dUMP</strong>, which <strong>inhibits thymidylate synthase</strong>, the enzyme responsible for converting <strong>dUMP to dTMP (thymidylate)</strong>.</span></p><p><span style=\"font-size:12.0pt;\">This inhibition <strong>prevents the formation of TMP</strong>, which is necessary for DNA synthesis. Without sufficient TMP, DNA replication stalls, particularly affecting rapidly dividing cells like cancer cells. This is why 5-FU is used to treat various solid tumors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span><br><br>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Understand how <strong>5-Fluorouracil targets thymidylate synthase</strong>, leading to inhibition of thymidine nucleotide (TMP) synthesis, thus impairing DNA replication in rapidly proliferating cells like tumors.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Also know that:</span></p><ul style=\"list-style-type:disc;\"><li><span style=\"font-size:12.0pt;\"><strong>Methotrexate</strong> indirectly affects TMP synthesis by inhibiting <strong>dihydrofolate reductase (DHFR)</strong>, reducing tetrahydrofolate availability for thymidylate synthesis.</span></li><li><span style=\"font-size:12.0pt;\"><strong>5-FU directly inhibits thymidylate synthase</strong>, making it a <strong>more targeted inhibitor</strong> of TMP production.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref</strong>: Vasudevan 9/e: p717.</span></p>",
      "correct_choice_id": 37303,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9338,
      "choices": [
        {
          "id": 37319,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-b, 3-c, 4-d</span></p>"
        },
        {
          "id": 37320,
          "text": "<p><span style=\"font-size:12.0pt;\">1-d, 2-c, 3-b, 4-a</span></p>"
        },
        {
          "id": 37321,
          "text": "<p><span style=\"font-size:12.0pt;\">1-a, 2-c, 3-d, 4-b</span></p>"
        },
        {
          "id": 37322,
          "text": "<p><span style=\"font-size:12.0pt;\">1-c, 2-d, 3-a, 4-b</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Match the following:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/05/screenshot-2024-04-05-151150.png\" alt=\"\" width=\"700\" height=\"205\"></span></p>",
      "unique_key": "Q8450641",
      "question_audio": null,
      "question_video": null,
      "map_id": 30371,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D. 1-c, 2-d, 3-a, 4-b</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>1-C</strong>: <strong>Gout</strong> is often caused by <strong>defects in purine metabolism,</strong> particularly involving PRPP synthetase and HGPRT. Overactivity of PRPP synthetase or deficiency in HGPRT leads to increased production of uric acid, which precipitates in joints causing gouty arthritis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>2-D: SCID </strong>(Severe Combined Immunodeficiency) can result from a <strong>deficiency in ADA</strong> (Adenosine Deaminase), which leads to an accumulation of toxic metabolites harmful to lymphocytes, resulting in severe immunodeficiency.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>3-A: Orotic Aciduria</strong> is characterized by <strong>megaloblastic anemia</strong> and the <strong>excretion of large amounts of orotic acid</strong> in <strong>urine</strong> due to a defect in the de novo pyrimidine synthesis pathway, specifically in the enzymes OPRTase and OMP decarboxylase.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>4-B: Renal lithiasis</strong> (Kidney Stones) can occur due to an <strong>APRT </strong>(Adenine Phosphoribosyltransferase) <strong>deficiency,</strong> leading to the formation of 2,8-dihydroxyadenine stones, a condition often misdiagnosed as uric acid stones.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/05/screenshot-2024-04-05-151218.png\" alt=\"\" width=\"700\" height=\"207\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Ref</u>: Vasudevan 9/e: p 583.</strong></span></p>",
      "correct_choice_id": 37322,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 9343,
      "choices": [
        {
          "id": 37339,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A and R both are right but R is not the correct explanation of A</span></span></span></p>"
        },
        {
          "id": 37340,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A as well as R are right and R is a correct explanation of A </span></span></span></p>"
        },
        {
          "id": 37341,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A is right but R is a wrong statement</span></span></span></p>"
        },
        {
          "id": 37342,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A and R both are wrong</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Assertion (A)</span></strong><span style=\"font-size:12.0pt\">: Urea Cycle Disorder and Orotic Aciduria are interlinked.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Reasoning (R)</span></strong><span style=\"font-size:12.0pt\">: Orotic aciduria occurs in ornithine transcarbamoylase deficiency (a urea cycle enzyme) due to the accumulation of carbamoyl phosphate, which then enters the cytosol and serves as a substrate for pyrimidine biosynthesis. Which of the following is correct?</span></span></span></p>",
      "unique_key": "Q4229727",
      "question_audio": null,
      "question_video": null,
      "map_id": 30373,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">. B. </span></strong><strong><span style=\"font-size:12.0pt\">A as well as R, are right and R is a correct explanation of A </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Urea Cycle Disorder</strong> and <strong>Orotic Aciduria</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Deficiency</strong> in <strong>liver mitochondrial enzyme ornithine transcarbamoylase</strong> &rarr; <strong>excess carbamoyl phosphate</strong> in the <strong>mitochondria</strong> &rarr; which then <strong>exits to the cytosol</strong>, where it <strong>stimulates pyrimidine nucleotide.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Orotic aciduria </strong>may also occur in <strong>ornithine transcarbamoylase deficiency</strong> (urea cycle enzyme) causes <strong>carbamoyl phosphate</strong> to <strong>accumulate</strong> due to <strong>defective conversion to citrulline.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/11/17.jpg\" style=\"height:348px; width:602px\" /></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Urea cycle disorders</strong>, such as <strong>ornithine transcarbamoylase</strong> (OTC) <strong>deficiency</strong>, can lead to the <strong>accumulation of carbamoyl phosphate,</strong> which can then <strong>spill over into the cytosol</strong> and be used as a <strong>substrate for pyrimidine biosynthesis,</strong> resulting in orotic aciduria.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Ref</span></u></strong><strong><span style=\"font-size:12.0pt\">: Vasudevan 9/e: P 587.</span></strong></span></span></p>",
      "correct_choice_id": 37340,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17944,
      "choices": [
        {
          "id": 71735,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibit thymidylate synthase</span></p>"
        },
        {
          "id": 71736,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits dihydrofolate reductase</span></p>"
        },
        {
          "id": 71737,
          "text": "<p><span style=\"font-size:12.0pt;\">Availability of amp is reduced</span></p>"
        },
        {
          "id": 71738,
          "text": "<p><span style=\"font-size:12.0pt;\">Causing cross linkage between adjacent bases of the double helix</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 4-year-old boy is brought to the clinic by his parents due to pain in both lower limbs and a noticeable limp that has persisted for the past three months. After a thorough examination and diagnostic tests, he is diagnosed with osteosarcoma in his right femur. To treat his condition, the oncologist prescribes methotrexate among other antineoplastic drugs as part of his chemotherapy regimen. Given this scenario, what is the mechanism of action of methotrexate in the treatment of osteosarcoma?</span></p>",
      "unique_key": "Q9295166",
      "question_audio": null,
      "question_video": null,
      "map_id": 30370,
      "difficulty_level": "beginner",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B. Inhibits dihydrofolate reductase</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Methotrexate is a structural analog of folic acid that competitively and reversibly inhibits dihydrofolate reductase (DHFR). This enzyme is essential for converting dihydrofolate (DHF) to tetrahydrofolate (THF). When DHFR is inhibited:</span></p><ol><li><span style=\"font-size:12.0pt;\">Tetrahydrofolate levels decrease, preventing the formation of one-carbon donors like N5,N10-methylene-THF</span></li><li><span style=\"font-size:12.0pt;\">Without these methyl donors, thymidylate synthase cannot convert deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP)</span></li><li><span style=\"font-size:12.0pt;\">This leads to decreased thymidylate synthesis and subsequent disruption of DNA synthesis</span></li><li><span style=\"font-size:12.0pt;\">Additionally, purine synthesis is also affected as THF derivatives are required for purine ring formation</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">This mechanism is particularly effective against rapidly dividing cells such as cancer cells in osteosarcoma, which have high requirements for DNA synthesis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img class=\"image_resized\" style=\"aspect-ratio:600/327;width:100%;\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/12/screenshot-2024-04-12-155925.png\" alt=\"\" width=\"600\" height=\"327\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A</strong>: Inhibit thymidylate synthase While methotrexate indirectly affects thymidylate synthase function by depleting its cofactor (N5,N10-methylene-THF), it does not directly inhibit this enzyme. Drugs that directly inhibit thymidylate synthase include 5-fluorouracil (5-FU) and raltitrexed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C</strong>: Availability of AMP is reduced Methotrexate does indirectly affect purine synthesis, which could eventually impact AMP availability. However, this is a secondary effect and not the primary mechanism of action. The reduced availability of THF affects the purine ring formation, but this description is imprecise and incomplete compared to the DHFR inhibition mechanism.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D</strong>: Causing cross linkage between adjacent bases of the double helix This describes the mechanism of action of alkylating agents (such as cyclophosphamide, cisplatin) and some antibiotics (like mitomycin C). These agents form covalent bonds between DNA strands, preventing DNA replication and transcription. Methotrexate does not interact directly with DNA in this manner.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong>&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Methotrexate is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate cofactors. This disrupts one-carbon transfer reactions crucial for the synthesis of thymidylate, purines, and certain amino acids (methionine, glycine). The resultant impairment of DNA, RNA, and protein synthesis makes methotrexate effective against rapidly proliferating malignant cells like those in osteosarcoma.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref</strong>: DM Vasudevan 9/e: p 514,716,717.</span></p>",
      "correct_choice_id": 71736,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 17941,
      "choices": [
        {
          "id": 71724,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibit thymidylate synthase</span></p>"
        },
        {
          "id": 71725,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibits dihydrofolate reductase.</span></p>"
        },
        {
          "id": 71726,
          "text": "<p><span style=\"font-size:12.0pt;\">Availability of AMP is reduced</span></p>"
        },
        {
          "id": 71727,
          "text": "<p><span style=\"font-size:12.0pt;\">Causing cross linkage between adjacent bases of the double helix</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old male with a 6-month history of lower abdominal pain, bloody stools, loss of appetite, and weight loss undergoes a colonoscopy, which reveals a descending colonic mass. A biopsy confirms adenocarcinoma of the colon. Based on the diagnosis, the oncologist decides to prescribe 5-fluorouracil (5-FU) as part of the treatment regimen. Considering the patient's diagnosis and the prescribed medication, what is the mechanism of action of 5-fluorouracil (5-FU) as an antineoplastic agent?</span></p>",
      "unique_key": "Q3922134",
      "question_audio": null,
      "question_video": null,
      "map_id": 30368,
      "difficulty_level": "intermediate",
      "subjects_id": [
        1
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A. Inhibit thymidylate synthase</strong></span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option A:</strong></span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">5-Fluorouracil (5-FU) is a pyrimidine analog structurally similar to <strong>uracil</strong> and <strong>thymine</strong>. Inside cells, 5-FU is converted to <strong>fluoro-deoxyuridine monophosphate (FdUMP)</strong>, which permanently bound to <strong>thymidylate synthase</strong>. This inhibits the enzyme <strong>thymidylate synthase</strong>, preventing the methylation of <strong>deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP)</strong>. As a result, <strong>thymidine</strong> is not synthesized, halting <strong>DNA synthesis</strong>, which is particularly lethal to rapidly dividing cancer cells.</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong><u>Explanation</u></strong>:</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Inhibits dihydrofolate reductase</strong>: This is the mechanism of action of drugs like methotrexate, not 5-FU. Dihydrofolate reductase inhibitors block the formation of tetrahydrofolate, essential for nucleotide synthesis.</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Availability of AMP is reduced</strong>: This is not a recognized mechanism of action for 5-FU. 5-FU primarily affects thymidine synthesis rather than adenosine monophosphate (AMP).</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Causing cross-linkage between adjacent bases of the double helix</strong>: This describes the mechanism of action of alkylating agents like cyclophosphamide, not 5-FU. Alkylating agents cause cross-links in DNA, leading to strand breaks and cell death.</span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p><span style=\"font-size:12.0pt;\">&nbsp;</span></p><p><span style=\"font-size:12.0pt;\">5-Fluorouracil (5-FU) is an antimetabolite that acts primarily by inhibiting thymidylate synthase, resulting in decreased thymidine synthesis and subsequent DNA synthesis inhibition. This mechanism makes it effective against rapidly dividing cells, such as those in colorectal adenocarcinoma.&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref</strong>: DM Vasudevan 9/e: p 717.</span></p>",
      "correct_choice_id": 71724,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}